After JPM, biotechs still scrambling for IPOs as Kaleido, Cirius file amid government shutdown

We saw a flurry of initial public offering activity in the lead-up to the J.P. Morgan Healthcare Conference, but it seems as the dust settles on another chaotic week, biotechs are not standing still.

At the start of this year’s meeting in San Francisco, three early-through-late-stage biotechs wanted nearly $300 million between them. At the end of the week, two more have joined them: Kaleido Biosciences and Cirius Therapeutics.